Avenue Therapeutics Inc
Avenue Therapeutics, Inc., a specialty pharmaceutical company, focuses on the development and commercialization of therapies for the treatment of neurologic diseases. The company product candidates include AJ201, which is in a Phase 1b/2a clinical trial for the treatment of spinal and bulbar muscular atrophy; and intravenous tramadol for the treatment of post-operative acute pain. It also develop… Read more
Avenue Therapeutics Inc (ATXI) - Cash Flow Conversion Efficiency
Latest cash flow conversion efficiency as of September 2025: 0.166x
Based on the latest financial reports, Avenue Therapeutics Inc (ATXI) has a cash flow conversion efficiency ratio of 0.166x as of September 2025.
Cash flow conversion efficiency measures how effectively a company's net assets (equity) generate operating cash flow. It is calculated by dividing operating cash flow ($383.00K) by net assets ($2.30 Million). A higher ratio indicates that the company is more efficient at using its equity to generate cash flow from its core operations.
Avenue Therapeutics Inc - Cash Flow Conversion Efficiency Trend (2015–2024)
This chart illustrates how Avenue Therapeutics Inc's cash flow conversion efficiency has evolved over time, based on yearly financial data. Explore and compare other companies by cash flow conversion efficiency.
Avenue Therapeutics Inc Competitors by Cash Flow Conversion Efficiency
The table below lists competitors of Avenue Therapeutics Inc ranked by their cash flow conversion efficiency.
| Company | Cash Flow Conversion Efficiency |
|---|---|
|
SYSCO - Dusseldorf Stock Exchang
DU:SYY
|
0.024x |
|
M Vision Public Company Limited
BK:MVP
|
1.481x |
|
WACKER CHEMIE - Dusseldorf Stock Exchang
DU:WCH
|
0.045x |
|
Hypoport AG
STU:HYQ
|
0.026x |
|
Glucose Health Inc
PINK:GLUC
|
0.004x |
|
ITRON (IT6.SG)
STU:IT6
|
0.048x |
|
SODEP-Marsa Maroc
BC:SODEP-Marsa-Maroc
|
N/A |
|
Archidply Decor Limited
NSE:ADL
|
0.012x |
Annual Cash Flow Conversion Efficiency for Avenue Therapeutics Inc (2015–2024)
The table below shows the annual cash flow conversion efficiency of Avenue Therapeutics Inc from 2015 to 2024.
| Year | Net Assets | Operating Cash Flow | Cash Flow Conversion Efficiency | Change |
|---|---|---|---|---|
| 2024-12-31 | $1.86 Million | $-9.03 Million | -4.863x | +66.35% |
| 2023-12-31 | $654.00K | $-9.45 Million | -14.451x | -521.34% |
| 2022-12-31 | $3.27 Million | $-7.60 Million | -2.326x | -114.03% |
| 2021-12-31 | $3.45 Million | $-3.75 Million | -1.087x | +44.43% |
| 2020-12-31 | $2.36 Million | $-4.61 Million | -1.955x | +49.36% |
| 2019-12-31 | $6.80 Million | $-26.26 Million | -3.862x | -113.38% |
| 2018-12-31 | $-631.00K | $-18.22 Million | 28.868x | +8325.09% |
| 2017-12-31 | $19.38 Million | $-6.80 Million | -0.351x | -277.38% |
| 2016-12-31 | $-8.25 Million | $-1.63 Million | 0.198x | +13.52% |
| 2015-12-31 | $-5.13 Million | $-895.00K | 0.174x | -- |